<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Gastroenterology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/gi/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Aspirin use doesn&#8217;t curb peptic ulcer healing</title>
		<link>http://www.thedoctorschannel.com/view/aspirin-use-doesnt-curb-peptic-ulcer-healing/</link>
		<pubDate>Tue, 15 May 2012 18:56:57 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[aspirin]]></category>
		<category><![CDATA[esomeprazole]]></category>
		<category><![CDATA[peptic ulcer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31795</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; In patients with aspirin-related peptic ulcers, ulcer healing rates are comparable after esomeprazole therapy with or without aspirin continuation, Taiwanese researchers report in an April 17th on-line paper in The American Journal of Gastroenterology. In fact, the investigators suggest that &#8220;continuing low-dose aspirin plus a proton pump inhibitor is the -]]></description>
		
			<media:content duration="1:34" medium="video">
		<media:title><![CDATA[Aspirin use doesn&#8217;t curb peptic ulcer healing]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; In patients with aspirin-related peptic ulcers, ulcer healing rates are comparable after esomeprazole therapy with or without aspirin continuation, Taiwanese researchers report in an April 17th on-line paper in The American Journal of Gastroenterology. In fact, the investigators suggest that &#8220;continuing low-dose aspirin plus a proton pump inhibitor is the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/aspirin-use-doesnt-curb-peptic-ulcer-healing/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120515clin005.jpg"/>
	<media:keywords><![CDATA[aspirin,esomeprazole,peptic ulcer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Risk/benefit of anticoagulation generally neutral in AF with GI ulcer</title>
		<link>http://www.thedoctorschannel.com/view/riskbenefit-of-anticoagulation-generally-neutral-in-af-with-gi-ulcer-3/</link>
		<pubDate>Tue, 01 May 2012 23:09:58 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[anticoagulation]]></category>
		<category><![CDATA[atrial fibrillation]]></category>
		<category><![CDATA[gastric ulcer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30459</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For patients with atrial fibrillation and previous GI ulcers, a higher risk of major bleeding with oral anticoagulation is balanced out by a lower rate of thromboembolic and cardiac events, a Korean team reports in the America Journal of Cardiology online April 18. However, “In this study, the incidence of -]]></description>
		
			<media:content duration="1:34" medium="video">
		<media:title><![CDATA[Risk/benefit of anticoagulation generally neutral in AF with GI ulcer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For patients with atrial fibrillation and previous GI ulcers, a higher risk of major bleeding with oral anticoagulation is balanced out by a lower rate of thromboembolic and cardiac events, a Korean team reports in the America Journal of Cardiology online April 18. However, “In this study, the incidence of -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/riskbenefit-of-anticoagulation-generally-neutral-in-af-with-gi-ulcer-3/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120501clin001.jpg"/>
	<media:keywords><![CDATA[AF,anticoagulation,atrial fibrillation,gastric ulcer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adjuvant therapy beneficial in high-risk biliary tract tumors: meta-analysis</title>
		<link>http://www.thedoctorschannel.com/view/adjuvant-therapy-beneficial-in-high-risk-biliary-tract-tumors-meta-analysis/</link>
		<pubDate>Fri, 27 Apr 2012 19:07:48 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[adjuvant therapy]]></category>
		<category><![CDATA[Biliary tumor]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30276</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer with high-risk features, researchers conclude. “We found from our review that adjuvant therapy, mainly chemotherapy, appears to offer a survival advantage to those patients with biliary cancer -]]></description>
		
			<media:content duration="1:31" medium="video">
		<media:title><![CDATA[Adjuvant therapy beneficial in high-risk biliary tract tumors: meta-analysis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer with high-risk features, researchers conclude. “We found from our review that adjuvant therapy, mainly chemotherapy, appears to offer a survival advantage to those patients with biliary cancer -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adjuvant-therapy-beneficial-in-high-risk-biliary-tract-tumors-meta-analysis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120427clin0021.jpg"/>
	<media:keywords><![CDATA[adjuvant therapy,Biliary tumor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Risk of small bowel obstruction less with laparoscopic than open surgery</title>
		<link>http://www.thedoctorschannel.com/view/risk-of-small-bowel-obstruction-less-with-laparoscopic-than-open-surgery/</link>
		<pubDate>Fri, 20 Apr 2012 21:37:40 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[appendectomy]]></category>
		<category><![CDATA[Bariatric Surgery]]></category>
		<category><![CDATA[bowel resection]]></category>
		<category><![CDATA[cholecystectomy]]></category>
		<category><![CDATA[hysterectomy]]></category>
		<category><![CDATA[laparoscopy]]></category>
		<category><![CDATA[rectal resection]]></category>
		<category><![CDATA[rectopexy]]></category>
		<category><![CDATA[salpingo-oophorectomy]]></category>
		<category><![CDATA[SBO]]></category>
		<category><![CDATA[small bowel obstruction]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28402</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The likelihood of small bowel obstruction (SBO) developing because of adhesions following abdominal or pelvic surgery is generally lower with laparoscopic procedures than with open operations, a Swedish team reports in the April issue of the Archives of Surgery. “This study shows that, beyond important factors such as age, previous -]]></description>
		
			<media:content duration="1:37" medium="video">
		<media:title><![CDATA[Risk of small bowel obstruction less with laparoscopic than open surgery]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The likelihood of small bowel obstruction (SBO) developing because of adhesions following abdominal or pelvic surgery is generally lower with laparoscopic procedures than with open operations, a Swedish team reports in the April issue of the Archives of Surgery. “This study shows that, beyond important factors such as age, previous -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/risk-of-small-bowel-obstruction-less-with-laparoscopic-than-open-surgery/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120420clin003.jpg"/>
	<media:keywords><![CDATA[appendectomy,Bariatric Surgery,bowel resection,cholecystectomy,hysterectomy,laparoscopy,rectal resection,rectopexy,salpingo-oophorectomy,SBO,small bowel obstruction]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Sleeve gastrectomy better than medical therapy for obesity-related diabetes</title>
		<link>http://www.thedoctorschannel.com/view/sleeve-gastrectomy-better-than-medical-therapy-for-obesity-related-diabetes/</link>
		<pubDate>Thu, 19 Apr 2012 22:03:24 +0000</pubDate> 
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Gastrectomy]]></category>
		<category><![CDATA[obesity]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28392</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Sleeve gastrectomy leads to significant improvement or resolution of type 2 diabetes in morbidly obese patients, and is much more effective than intensive conventional medical therapy, confirms a comparative study of patients treated at the Centre for the Surgical-Medical Treatment of Morbid Obesity, Policlinico &#8220;Umberto I,&#8221; University of Rome &#8220;Sapienza,&#8221; -]]></description>
		
			<media:content duration="1:41" medium="video">
		<media:title><![CDATA[Sleeve gastrectomy better than medical therapy for obesity-related diabetes]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Sleeve gastrectomy leads to significant improvement or resolution of type 2 diabetes in morbidly obese patients, and is much more effective than intensive conventional medical therapy, confirms a comparative study of patients treated at the Centre for the Surgical-Medical Treatment of Morbid Obesity, Policlinico &#8220;Umberto I,&#8221; University of Rome &#8220;Sapienza,&#8221; -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/sleeve-gastrectomy-better-than-medical-therapy-for-obesity-related-diabetes/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120419clin001.jpg"/>
	<media:keywords><![CDATA[diabetes,Gastrectomy,obesity]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Doubled dose of rabeprazole increases cure rate of refractory esophagitis</title>
		<link>http://www.thedoctorschannel.com/view/doubled-dose-of-rabeprazole-increases-cure-rate-of-refractory-esophagitis/</link>
		<pubDate>Thu, 12 Apr 2012 22:40:05 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[esophagitis]]></category>
		<category><![CDATA[Rabeprazole]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28017</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A Japanese team has confirmed endoscopically that when a standard once-daily dose of rabeprazole fails to resolve reflux esophagitis, a twice-daily regimen may be more successful. “In subgroup analyses, the endoscopically confirmed healing rates were higher in the RPZ (rabeprazole) 10 and 20 mg b.i.d. groups than in the 20 -]]></description>
		
			<media:content duration="1:24" medium="video">
		<media:title><![CDATA[Doubled dose of rabeprazole increases cure rate of refractory esophagitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A Japanese team has confirmed endoscopically that when a standard once-daily dose of rabeprazole fails to resolve reflux esophagitis, a twice-daily regimen may be more successful. “In subgroup analyses, the endoscopically confirmed healing rates were higher in the RPZ (rabeprazole) 10 and 20 mg b.i.d. groups than in the 20 -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/doubled-dose-of-rabeprazole-increases-cure-rate-of-refractory-esophagitis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120412drgd0071.jpg"/>
	<media:keywords><![CDATA[esophagitis,Rabeprazole]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adjuvant cetuximab improves some outcomes of high-risk rectal cancer</title>
		<link>http://www.thedoctorschannel.com/view/adjuvant-cetuximab-improves-some-outcomes-of-high-risk-rectal-cancer-2/</link>
		<pubDate>Thu, 12 Apr 2012 22:27:22 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[CAPOX]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[oxaliplatin]]></category>
		<category><![CDATA[rectal cancer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28010</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal cancer. However, it does not improve complete response rates, according to a report in the April 2nd online issue of the Journal of Clinical Oncology. While the -]]></description>
		
			<media:content duration="1:24" medium="video">
		<media:title><![CDATA[Adjuvant cetuximab improves some outcomes of high-risk rectal cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal cancer. However, it does not improve complete response rates, according to a report in the April 2nd online issue of the Journal of Clinical Oncology. While the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adjuvant-cetuximab-improves-some-outcomes-of-high-risk-rectal-cancer-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120412drgd006.jpg"/>
	<media:keywords><![CDATA[capecitabine,CAPOX,cetuximab,oxaliplatin,rectal cancer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adjuvant cetuximab improves some outcomes of high-risk rectal cancer</title>
		<link>http://www.thedoctorschannel.com/view/adjuvant-cetuximab-improves-some-outcomes-of-high-risk-rectal-cancer/</link>
		<pubDate>Wed, 11 Apr 2012 21:18:49 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[CAPOX]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[oxaliplatin]]></category>
		<category><![CDATA[rectal cancer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27967</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal cancer. However, it does not improve complete response rates, according to a report in the April 2nd online issue of the Journal of Clinical Oncology. While the -]]></description>
		
			<media:content duration="1:37" medium="video">
		<media:title><![CDATA[Adjuvant cetuximab improves some outcomes of high-risk rectal cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A multicenter center study has shown that adding cetuximab to neoadjuvant chemotherapy and preoperative radiotherapy improves overall survival after excision of high-risk rectal cancer. However, it does not improve complete response rates, according to a report in the April 2nd online issue of the Journal of Clinical Oncology. While the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adjuvant-cetuximab-improves-some-outcomes-of-high-risk-rectal-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120411drgd005.jpg"/>
	<media:keywords><![CDATA[capecitabine,CAPOX,cetuximab,oxaliplatin,rectal cancer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Fecal microbiota transplant effective for recurrent C difficile infection</title>
		<link>http://www.thedoctorschannel.com/view/fecal-microbiota-transplant-effective-for-recurrent-c-difficile-infection/</link>
		<pubDate>Tue, 10 Apr 2012 23:06:18 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[c difficile]]></category>
		<category><![CDATA[Fecal transplant]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27891</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Instillation of donor fecal material in the colon of patients with recurrent Clostridium difficile infection leads to rapid resolution of the condition in more than 90% of cases, investigators report in the American Journal of Gastroenterology online March 29. “Evidence continues to mount showing that FMT (fecal microbiota transplant) is -]]></description>
		
			<media:content duration="1:39" medium="video">
		<media:title><![CDATA[Fecal microbiota transplant effective for recurrent C difficile infection]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Instillation of donor fecal material in the colon of patients with recurrent Clostridium difficile infection leads to rapid resolution of the condition in more than 90% of cases, investigators report in the American Journal of Gastroenterology online March 29. “Evidence continues to mount showing that FMT (fecal microbiota transplant) is -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/fecal-microbiota-transplant-effective-for-recurrent-c-difficile-infection/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120410drgd001.jpg"/>
	<media:keywords><![CDATA[c difficile,Fecal transplant]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>No benefit adding cetuximab to chemo after colon cancer resection</title>
		<link>http://www.thedoctorschannel.com/view/no-benefit-adding-cetuximab-to-chemo-after-colon-cancer-resection/</link>
		<pubDate>Thu, 05 Apr 2012 22:33:25 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[fluorouracil]]></category>
		<category><![CDATA[FOLFOX]]></category>
		<category><![CDATA[leucovorin]]></category>
		<category><![CDATA[oxaliplatin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27645</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX), according to study findings published in the Journal of the American Medical Association for April 4. “Patient enrollment began February 10, 2004, and was permanently halted -]]></description>
		
			<media:content duration="1:40" medium="video">
		<media:title><![CDATA[No benefit adding cetuximab to chemo after colon cancer resection]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX), according to study findings published in the Journal of the American Medical Association for April 4. “Patient enrollment began February 10, 2004, and was permanently halted -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/no-benefit-adding-cetuximab-to-chemo-after-colon-cancer-resection/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120403drgd004.jpg"/>
	<media:keywords><![CDATA[cetuximab,colon cancer,fluorouracil,FOLFOX,leucovorin,oxaliplatin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
